Developer docs
API playgroundTry for free, no card

Search company profiles

Seegene Technologies

Full company profile

uuid000vv5w

Namestring
Seegene Technologies
Legal namestring
Seegene, Inc.
Websiteurl
seegenetech.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Seegene Technologies is the US operating subsidiary of Seegene, Inc., a Seoul-headquartered molecular diagnostics company founded in 2000 and listed on KOSDAQ since 2010 under ticker KQ096530. The company develops proprietary multiplex real-time PCR technologies—DPO (Dual Priming Oligonucleotide), TOCE (Tagging Oligonucleotide Cleavage Extension), and MuDT (the world's first real-time PCR providing individual Ct values for multiple targets in a single channel without melt-curve analysis)—enabling simultaneous detection of up to 14 pathogens in a single reaction tube with quantitative results. Its product portfolio spans IVDR-certified Allplex assay panels for respiratory, gastrointestinal, STI, HPV, and antimicrobial resistance testing; Novaplex research-use assays for emerging pathogens including mpox; automation instruments (STARlet-AIOS, NIMBUS, and the fully unattended CURECA platform with modular CPS, PAS, and CEFA units); and the SG STATS analytical software layer.

The company's commercial model has shifted decisively toward the SG OneSystem technology-sharing platform, under which Seegene establishes jointly-controlled NewCo entities with leading national diagnostic companies—Hylabs in Israel (March 2023) and Werfen in Spain (May 2025)—granting them access to assay design, automation, validation, and AI-enabled development capabilities in exchange for localized manufacturing, distribution, and revenue participation. The SGDDS (Seegene Digitalized Development System) integrates Microsoft Azure OpenAI, Microsoft Fabric, and related services to automate reagent development and syndromic data analytics. Revenue is generated through technology licensing and royalties on NewCo commercialization, sale of IVDR assays outside the USA, and hardware sales of automation platforms. End-customers include hospital and clinical laboratories, government health agencies, and the NewCo partners themselves; the firm has supplied more than 340 million COVID-19 tests across 100+ countries and operates the Open Innovation Program jointly with Springer Nature. The US entity was established in Irvine, California in June 2025 as the beachhead for the technology-sharing model in the US market.

Short descriptiontext

Seegene Technologies is the US operating arm of Seegene, Inc., a Korean molecular diagnostics company that develops proprietary multiplex PCR assays, automation systems, and an AI-enabled development platform, serving clinical laboratories and national diagnostic partners worldwide through its SG OneSystem technology-sharing joint-venture model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, multiplex PCR assays, automated testing systems, diagnostic reagents, syndromic PCR technology
Industry2 codes
PRIMARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAHAOAJ
Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing and NewCo Partnerships
TypeLicensing Royalties
Description

Seegene shares its advanced diagnostic and data analysis technologies (syndromic real-time PCR and SGDDS) with leading companies partnered in each country through joint venture NewCos. Partners develop, manufacture, and distribute localized diagnostic products.

seegenetech.com
2Diagnostic Reagent Sales
TypeOne Time License
Description

Sale of multiplex PCR assay products including IVDR assays for respiratory infections, gastrointestinal infections, STIs, HPV, and antimicrobial resistance. Products include Allplex brand assays sold globally.

seegenetech.com
3Automated Testing Systems
TypeHardware Sales
Description

Sale and distribution of automated molecular diagnostic testing systems including STARlet-AIOS, NIMBUS, and CURECA platforms for laboratories of various sizes.

seegenetech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1Allplex
Description

High-multiplex real-time PCR assay products for various infections including respiratory, gastrointestinal, STI, HPV, and antimicrobial resistance testing

seegenetech.com
+9 more records
Core offering1 text field

Seegene Technologies develops and manufactures multiplex PCR molecular diagnostic assays (under brands such as Allplex and Novaplex) and automated testing systems (STARlet-AIOS, NIMBUS, CURECA) for clinical laboratories and healthcare providers. The company operates the SG OneSystem technology-sharing model, partnering with national diagnostic companies through NewCo joint ventures to develop, manufacture, and commercialize localized syndromic PCR products covering respiratory infections, gastrointestinal infections, sexually transmitted infections, HPV, and antimicrobial resistance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Simultaneous detection of 14 pathogens in a single reaction tube with quantitative information
+3 more records
Product overview1 text field

Seegene Technologies offers a comprehensive molecular diagnostics ecosystem centered on syndromic real-time PCR technology. The portfolio includes the SG OneSystem™ technology-sharing platform and SGDDS automated development system, supported by automation instruments (STARlet-AIOS™, NIMBUS, CURECA™) and core technologies (DPO™, TOCE™, MuDT™). The product line spans IVDR assay panels for respiratory infections (RP), gastrointestinal infections (GI), sexually transmitted infections (STI), HPV, and antimicrobial resistance (AMR), alongside specialized instruments (CPS, PAS, CEFA) and analytical tools (SG STATS). The company positions itself as a total PCR solution provider enabling simultaneous detection of up to 14 pathogens in a single tube.

Product and service10 records
1Allplex HPV HR Detection
CategoryDiagnostic Reagents / Molecular Assays
Description

Real-time PCR assay designed to test for 14 high-risk HPV types, including types 16 and 18, in a single tube. Intended for cervical cancer prevention and follow-up management in clinical laboratories and screening programs.

2Allplex HPV28 Detection
CategoryDiagnostic Reagents / Molecular Assays
Description

Real-time PCR assay designed to test for 28 HPV types (19 high-risk and 9 low-risk) in two tubes, providing individual genotypes and Ct values in one test for comprehensive cervical cancer screening and HPV genotyping.

3Novaplex MPXV Assay (RUO)
CategoryDiagnostic Reagents / Molecular Assays
Description

Research-use-only PCR assay designed to detect mpox virus (MPXV), developed in 2022 using Seegene's SGDDS system for early mpox detection capability.

4Novaplex MPXV/OPXV plus Assay (RUO)
CategoryDiagnostic Reagents / Molecular Assays
Description

Research-use-only PCR assay designed to detect MPXV Clade I (higher transmission/mortality) with specific confirmation, OPXV, and MPXV Clade II, meeting WHO target product profiles for mpox detection.

5Novaplex HSV-1&2/VZV/MPXV Assay (RUO)
CategoryDiagnostic Reagents / Molecular Assays
Description

Research-use-only multiplex PCR assay designed to detect four viruses simultaneously: MPXV, herpes simplex virus types 1 and 2, and varicella-zoster virus (VZV).

6STARlet-AIOS
CategoryAutomated Testing Instruments
Description

Fully automated molecular diagnostic testing system that streamlines the entire PCR process from nucleic acid extraction to result analysis, featuring a modular design that integrates existing instruments for clinical laboratories.

7Seegene NIMBUS
CategoryAutomated Testing Instruments
Description

Automated testing system providing automation solutions tailored to the size and throughput needs of various testing laboratories.

8CURECA
CategoryAutomated Testing Instruments
Description

Seegene's fully automated molecular diagnostics platform designed to automate the entire PCR workflow including pre-treatment across diverse specimen types (stool, urine, blood, sputum) via its modular CPS, PAS, and CEFA subsystems, enabling fully unattended PCR automation.

9SG OneSystem Technology-Sharing Platform
CategoryTechnology Platform / Business Model
Description

Seegene's technology-sharing platform through which partner companies in each country gain access to Seegene's assay design, automation, and validation capabilities to develop, license, manufacture, and distribute localized syndromic PCR diagnostic products in their markets.

10SGDDS (Seegene Digitalized Development System)
CategorySoftware / Development Platform
Description

Seegene's automated diagnostic reagent development system that integrates Microsoft Azure AI services to streamline assay design, validation, and regulatory submission workflows for syndromic PCR products.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Partnership agreement to co-establish Werfen-Seegene NewCo in Spain as strategic hub in Europe. Werfen is worldwide leader in specialized diagnostics. NewCo will develop products for infectious diseases including antimicrobial resistance testing, viral load testing, STI detection, and emerging diseases. Expected to secure CE-IVDR approval and expand into European and global markets.

2UK Health Security Agency (UKHSA)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Prof. Dame Jenny Harries, Chief Executive of UKHSA, attended Seegene's Partner Executive Roundtable and visited Seegene headquarters in Korea to discuss pandemic response achievements and technology-sharing initiatives.

seegenetech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Strategic alliance to foster collaboration with researchers across various disease fields using Seegene's PCR diagnostic technology. Includes expansion of Open Innovation Program to Nature Awards MDx Impact Grants. Springer Nature promotes the program to global scientific community and oversees project submissions and evaluations.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-01
Description

Strategic collaboration to integrate Microsoft Azure AI solutions into Seegene's automated diagnostic reagent development system (SGDDS). Includes Azure OpenAI Service, Azure Trusted Research Environment, Microsoft Fabric analytics platform, and Copilot for Microsoft 365. Aims to empower global companies in the technology-sharing initiative with streamlined product development and AI-powered data analysis.

5International Vaccine Institute (IVI)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

MOU to utilize Seegene's HPV diagnostic reagents for Global HPV Burden Study testing approximately 50,000 people across eight Asian and African countries over five years. Study measures prevalence of 28 HPV types in women aged 9-50 to establish future cervical cancer vaccination policies. Supported by Bill & Melinda Gates Foundation.

seegenetech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-01
Description

First One System global partnership agreement with leading Israeli diagnostic company. Hylabs contributes five decades of leadership in molecular and microbiology diagnostics. Partnership enables localization of Seegene's syndromic PCR technologies to address local healthcare needs in Israel.

Recent move16 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Qiagen's QIAstat-Dx syndromic panels and sample-prep technologies directly compete with Seegene's multiplex PCR menus, and Qiagen also operates a partnered/OTG distribution model in several regions analogous to Seegene's NewCos.

TypeDirect peer
Description

BioFire's FilmArray panels (respiratory, GI, meningitis/encephalitis, blood culture identification) are the benchmark syndromic multiplex molecular diagnostics system, competing head-to-head with Seegene's Allplex offerings in the same hospital and reference lab customers.

TypeOthers
Description

Werfen is both a Seegene partner (newly forming the Spain NewCo JV in 2025) and a specialized-diagnostics incumbent with hemostasis, acute care and autoimmunity lines; inclusion is justified because the JV relationship makes them comparable in specialized IVD.

TypeBroad incumbent
Description

Roche operates cobas and the GenMark ePlex syndromic molecular platform (post GenMark acquisition), giving it a broad IVD portfolio overlapping with Seegene's syndromic multiplex PCR positioning.

TypeDirect peer
Description

DiaSorin's acquisition of Luminex brought the xTAG and xMAP multiplex molecular platforms used for respiratory, GI and STI syndromic panels, competing with Seegene's Allplex assays.

TypeBroad incumbent
Description

BD's MAX System and broader microbiology/molecular diagnostics portfolio competes with Seegene's syndromic PCR in hospital labs, and BD's scale in clinical instrumentation makes it a cross-capability incumbent.

TypeDirect peer
Description

Hologic's Panther system with Aptima and Panther Fusion assays competes with Seegene's molecular diagnostics in women's health (HPV/STI) and hospital molecular testing.

TypeBroad incumbent
Description

QuidelOrtho's Sofia and Savanna rapid molecular platforms, plus its broad IVD catalog, overlap with Seegene's syndromic infectious-disease testing menu and customer base.

9Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's m2000 and Alinity m molecular systems offer PCR-based infectious disease and STI testing at scale, putting it in the same hospital and reference-lab RFPs that Seegene targets.

TypeDirect peer
Description

Cepheid's GeneXpert system is a leading automated real-time PCR platform with Xpert syndromic panels (respiratory, GI, STI, AMR) overlapping directly with Seegene's reagent and instrument value proposition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Seegene Technologies

Molecular Diagnosticsseegenetech.com

Seegene Technologies is the US operating arm of Seegene, Inc., a Korean molecular diagnostics company that develops proprietary multiplex PCR assays, automation systems, and an AI-enabled development platform, serving clinical laboratories and national diagnostic partners worldwide through its SG OneSystem technology-sharing joint-venture model.

What Seegene Technologies does

Seegene Technologies is the US operating subsidiary of Seegene, Inc., a Seoul-headquartered molecular diagnostics company founded in 2000 and listed on KOSDAQ since 2010 under ticker KQ096530. The company develops proprietary multiplex real-time PCR technologies—DPO (Dual Priming Oligonucleotide), TOCE (Tagging Oligonucleotide Cleavage Extension), and MuDT (the world's first real-time PCR providing individual Ct values for multiple targets in a single channel without melt-curve analysis)—enabling simultaneous detection of up to 14 pathogens in a single reaction tube with quantitative results. Its product portfolio spans IVDR-certified Allplex assay panels for respiratory, gastrointestinal, STI, HPV, and antimicrobial resistance testing; Novaplex research-use assays for emerging pathogens including mpox; automation instruments (STARlet-AIOS, NIMBUS, and the fully unattended CURECA platform with modular CPS, PAS, and CEFA units); and the SG STATS analytical software layer.

The company's commercial model has shifted decisively toward the SG OneSystem technology-sharing platform, under which Seegene establishes jointly-controlled NewCo entities with leading national diagnostic companies—Hylabs in Israel (March 2023) and Werfen in Spain (May 2025)—granting them access to assay design, automation, validation, and AI-enabled development capabilities in exchange for localized manufacturing, distribution, and revenue participation. The SGDDS (Seegene Digitalized Development System) integrates Microsoft Azure OpenAI, Microsoft Fabric, and related services to automate reagent development and syndromic data analytics. Revenue is generated through technology licensing and royalties on NewCo commercialization, sale of IVDR assays outside the USA, and hardware sales of automation platforms. End-customers include hospital and clinical laboratories, government health agencies, and the NewCo partners themselves; the firm has supplied more than 340 million COVID-19 tests across 100+ countries and operates the Open Innovation Program jointly with Springer Nature. The US entity was established in Irvine, California in June 2025 as the beachhead for the technology-sharing model in the US market.

Seegene Technologies firmographics

Firmographics
Name
Seegene Technologies
Legal name
Seegene, Inc.
Website
https://seegenetech.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
Seegene Technologies is the US operating arm of Seegene, Inc., a Korean molecular diagnostics company that develops proprietary multiplex PCR assays, automation systems, and an AI-enabled development platform, serving clinical laboratories and national diagnostic partners worldwide through its SG OneSystem technology-sharing joint-venture model.
Ownership category
akta.pro rank

Seegene Technologies industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAHAOAJ
Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Molecular diagnostics
  • Multiplex PCR assays
  • Automated testing systems
  • Diagnostic reagents
  • Syndromic PCR technology

Where Seegene Technologies is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Seegene Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Technology Licensing and NewCo Partnerships: Seegene shares its advanced diagnostic and data analysis technologies (syndromic real-time PCR and SGDDS) with leading companies partnered in each country through joint venture NewCos. Partners develop, manufacture, and distribute localized diagnostic products.
  2. Diagnostic Reagent Sales: Sale of multiplex PCR assay products including IVDR assays for respiratory infections, gastrointestinal infections, STIs, HPV, and antimicrobial resistance. Products include Allplex brand assays sold globally.
  3. Automated Testing Systems: Sale and distribution of automated molecular diagnostic testing systems including STARlet-AIOS, NIMBUS, and CURECA platforms for laboratories of various sizes.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Seegene Technologies product offering

Product offering

Core offering

Seegene Technologies develops and manufactures multiplex PCR molecular diagnostic assays (under brands such as Allplex and Novaplex) and automated testing systems (STARlet-AIOS, NIMBUS, CURECA) for clinical laboratories and healthcare providers. The company operates the SG OneSystem technology-sharing model, partnering with national diagnostic companies through NewCo joint ventures to develop, manufacture, and commercialize localized syndromic PCR products covering respiratory infections, gastrointestinal infections, sexually transmitted infections, HPV, and antimicrobial resistance.

Product overview

Seegene Technologies offers a comprehensive molecular diagnostics ecosystem centered on syndromic real-time PCR technology. The portfolio includes the SG OneSystem™ technology-sharing platform and SGDDS automated development system, supported by automation instruments (STARlet-AIOS™, NIMBUS, CURECA™) and core technologies (DPO™, TOCE™, MuDT™). The product line spans IVDR assay panels for respiratory infections (RP), gastrointestinal infections (GI), sexually transmitted infections (STI), HPV, and antimicrobial resistance (AMR), alongside specialized instruments (CPS, PAS, CEFA) and analytical tools (SG STATS). The company positions itself as a total PCR solution provider enabling simultaneous detection of up to 14 pathogens in a single tube.

Differentiator

Problem solved

Functional benefit

Brands

  • Allplex: High-multiplex real-time PCR assay products for various infections including respiratory, gastrointestinal, STI, HPV, and antimicrobial resistance testing
  • CURECA
  • DPO
  • TOCE
  • MuDT
  • STARlet-AIOS
  • Seegene NIMBUS
  • SG STATS
  • SGDDS
  • Novaplex

Products and services

  • Allplex HPV HR Detection Real-time PCR assay designed to test for 14 high-risk HPV types, including types 16 and 18, in a single tube. Intended for cervical cancer prevention and follow-up management in clinical laboratories and screening programs.
  • Allplex HPV28 Detection Real-time PCR assay designed to test for 28 HPV types (19 high-risk and 9 low-risk) in two tubes, providing individual genotypes and Ct values in one test for comprehensive cervical cancer screening and HPV genotyping.
  • Novaplex MPXV Assay (RUO) Research-use-only PCR assay designed to detect mpox virus (MPXV), developed in 2022 using Seegene's SGDDS system for early mpox detection capability.
  • Novaplex MPXV/OPXV plus Assay (RUO) Research-use-only PCR assay designed to detect MPXV Clade I (higher transmission/mortality) with specific confirmation, OPXV, and MPXV Clade II, meeting WHO target product profiles for mpox detection.
  • Novaplex HSV-1&2/VZV/MPXV Assay (RUO) Research-use-only multiplex PCR assay designed to detect four viruses simultaneously: MPXV, herpes simplex virus types 1 and 2, and varicella-zoster virus (VZV).
  • STARlet-AIOS Fully automated molecular diagnostic testing system that streamlines the entire PCR process from nucleic acid extraction to result analysis, featuring a modular design that integrates existing instruments for clinical laboratories.
  • Seegene NIMBUS Automated testing system providing automation solutions tailored to the size and throughput needs of various testing laboratories.
  • CURECA Seegene's fully automated molecular diagnostics platform designed to automate the entire PCR workflow including pre-treatment across diverse specimen types (stool, urine, blood, sputum) via its modular CPS, PAS, and CEFA subsystems, enabling fully unattended PCR automation.
  • SG OneSystem Technology-Sharing Platform Seegene's technology-sharing platform through which partner companies in each country gain access to Seegene's assay design, automation, and validation capabilities to develop, license, manufacture, and distribute localized syndromic PCR diagnostic products in their markets.
  • SGDDS (Seegene Digitalized Development System) Seegene's automated diagnostic reagent development system that integrates Microsoft Azure AI services to streamline assay design, validation, and regulatory submission workflows for syndromic PCR products.

Quantifiable outcome

  • Simultaneous detection of 14 pathogens in a single reaction tube with quantitative information
  • +3 more outcomes

Companies that use Seegene Technologies

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Seegene Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Seegene Technologies partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • WerfencoreStrategic or Co-development Partner · 1 May 2025Partnership agreement to co-establish Werfen-Seegene NewCo in Spain as strategic hub in Europe. Werfen is worldwide leader in specialized diagnostics. NewCo will develop products for infectious diseases including antimicrobial resistance testing, viral load testing, STI detection, and emerging diseases. Expected to secure CE-IVDR approval and expand into European and global markets.
  • UK Health Security Agency (UKHSA)majorStrategic or Co-development Partner · 1 October 2024Prof. Dame Jenny Harries, Chief Executive of UKHSA, attended Seegene's Partner Executive Roundtable and visited Seegene headquarters in Korea to discuss pandemic response achievements and technology-sharing initiatives.
  • Springer NaturecoreStrategic or Co-development Partner · 1 May 2024Strategic alliance to foster collaboration with researchers across various disease fields using Seegene's PCR diagnostic technology. Includes expansion of Open Innovation Program to Nature Awards MDx Impact Grants. Springer Nature promotes the program to global scientific community and oversees project submissions and evaluations.
  • MicrosoftcoreTechnology or Integration · 1 January 2024Strategic collaboration to integrate Microsoft Azure AI solutions into Seegene's automated diagnostic reagent development system (SGDDS). Includes Azure OpenAI Service, Azure Trusted Research Environment, Microsoft Fabric analytics platform, and Copilot for Microsoft 365. Aims to empower global companies in the technology-sharing initiative with streamlined product development and AI-powered data analysis.
  • International Vaccine Institute (IVI)majorStrategic or Co-development Partner · 1 January 2024MOU to utilize Seegene's HPV diagnostic reagents for Global HPV Burden Study testing approximately 50,000 people across eight Asian and African countries over five years. Study measures prevalence of 28 HPV types in women aged 9-50 to establish future cervical cancer vaccination policies. Supported by Bill & Melinda Gates Foundation.
  • Hy Laboratories Ltd (Hylabs)coreStrategic or Co-development Partner · 1 March 2023First One System global partnership agreement with leading Israeli diagnostic company. Hylabs contributes five decades of leadership in molecular and microbiology diagnostics. Partnership enables localization of Seegene's syndromic PCR technologies to address local healthcare needs in Israel.

Scale indicators6 records

Recent moves16 records

Expansion highlights5 records

Seegene Technologies competitors and assessment

Company assessment

Direct peers

  • Qiagen: Qiagen's QIAstat-Dx syndromic panels and sample-prep technologies directly compete with Seegene's multiplex PCR menus, and Qiagen also operates a partnered/OTG distribution model in several regions analogous to Seegene's NewCos.
  • BioFire Diagnostics (bioMérieux): BioFire's FilmArray panels (respiratory, GI, meningitis/encephalitis, blood culture identification) are the benchmark syndromic multiplex molecular diagnostics system, competing head-to-head with Seegene's Allplex offerings in the same hospital and reference lab customers.
  • DiaSorin (Luminex): DiaSorin's acquisition of Luminex brought the xTAG and xMAP multiplex molecular platforms used for respiratory, GI and STI syndromic panels, competing with Seegene's Allplex assays.
  • Hologic: Hologic's Panther system with Aptima and Panther Fusion assays competes with Seegene's molecular diagnostics in women's health (HPV/STI) and hospital molecular testing.
  • Cepheid (Danaher): Cepheid's GeneXpert system is a leading automated real-time PCR platform with Xpert syndromic panels (respiratory, GI, STI, AMR) overlapping directly with Seegene's reagent and instrument value proposition.

Others

  • Werfen: Werfen is both a Seegene partner (newly forming the Spain NewCo JV in 2025) and a specialized-diagnostics incumbent with hemostasis, acute care and autoimmunity lines; inclusion is justified because the JV relationship makes them comparable in specialized IVD.

Broad incumbents

  • Roche Diagnostics: Roche operates cobas and the GenMark ePlex syndromic molecular platform (post GenMark acquisition), giving it a broad IVD portfolio overlapping with Seegene's syndromic multiplex PCR positioning.
  • Becton, Dickinson and Company (BD): BD's MAX System and broader microbiology/molecular diagnostics portfolio competes with Seegene's syndromic PCR in hospital labs, and BD's scale in clinical instrumentation makes it a cross-capability incumbent.
  • QuidelOrtho: QuidelOrtho's Sofia and Savanna rapid molecular platforms, plus its broad IVD catalog, overlap with Seegene's syndromic infectious-disease testing menu and customer base.
  • Abbott Diagnostics: Abbott's m2000 and Alinity m molecular systems offer PCR-based infectious disease and STI testing at scale, putting it in the same hospital and reference-lab RFPs that Seegene targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Seegene Technologies social profiles

Digital presence

Seegene Technologies compliance and trust

Trust signal

Compliance6 records

Seegene Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seegene Technologies leadership team

Management profile

Number of profiles

Profiles3 records

Seegene Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Seegene Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seegene Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seegene Technologies

What does Seegene Technologies do?

Seegene Technologies develops and manufactures multiplex PCR molecular diagnostic assays (under brands such as Allplex and Novaplex) and automated testing systems (STARlet-AIOS, NIMBUS, CURECA) for clinical laboratories and healthcare providers. The company operates the SG OneSystem technology-sharing model, partnering with national diagnostic companies through NewCo joint ventures to develop, manufacture, and commercialize localized syndromic PCR products covering respiratory infections, gastrointestinal infections, sexually transmitted infections, HPV, and antimicrobial resistance.

Is Seegene Technologies a public or private company?

Seegene Technologies is a public company. It is classified as public and is currently operating.

When was Seegene Technologies founded?

Seegene Technologies was founded in 2000. It employs 11 to 50 people.

Where is Seegene Technologies based?

Seegene Technologies is headquartered in Irvine, United States, in the North America region.

How does Seegene Technologies make money?

Three revenue lines are on record. Technology Licensing and NewCo Partnerships are the primary driver. The others are diagnostic Reagent Sales and automated Testing Systems.

Who are Seegene Technologies's main competitors?

Direct peers on record are Qiagen, BioFire Diagnostics (bioMérieux), DiaSorin (Luminex), Hologic and Cepheid (Danaher). Werfen is listed as an others. Broad incumbents are Roche Diagnostics, Becton, Dickinson and Company (BD), QuidelOrtho and Abbott Diagnostics.

Does Seegene Technologies have an API?

No public API is recorded for Seegene Technologies.

What industry is Seegene Technologies in?

Seegene Technologies's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAHAOAJ, Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels). Its NAICS code is 334516 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSeegene präsentiert das weltweit erste vollautomatisierte PCR-System und läutet auf der ADLM 2025 eine globale diagnostische Paradigmenwende einSeegene Inc. unveiled CURECA, the world's first fully automated PCR testing system that handles the entire testing process from sample preparation through data analysis without manual intervention, at the ADLM 2025 conference in Chicago from July 28-31, 2025. The company also introduced STAgora, a real-time PCR data analytics platform that aggregates testing data from hospitals worldwide to support clinical decision-making and track regional infection trends. Seegene plans to establish pilot partnerships with selected institutions by year-end and expand its U.S. presence through local subsidiaries including Seegene Technologies and Seegene CURECA.PR NewswireSeegene presenta en ADLM 2025 la primera automatización PCR autónoma del mundoSeegene Inc. presented CURECA™ and STAgora™ at the ADLM 2025 conference in Chicago from July 28–31, positioning the announcement as a transformative shift in the global diagnostic paradigm. CURECA™ is claimed to be the world's first fully autonomous PCR testing system, automating the entire process from sample storage through pre-treatment, nucleic acid extraction, amplification, and result analysis without any human intervention, designed to operate continuously 24/7. Seegene plans to expand access through pilot programs with selected institutions before year-end and has established US subsidiaries including Seegene Technologies and Seegene CURECA to strengthen its R&D and manufacturing capabilities in the United States.PR NewswireFirma Seegene przedstawia pierwsze na świecie zautomatyzowane urządzenie do przeprowadzania testów PCR, które nie wymaga obsługi, zapoczątkowując globalną zmianę paradygmatu diagnostycznego podczas koSeegene Inc., a South Korean molecular diagnostics leader, announced at ADLM 2025 in Chicago the launch of CURECA™, the world's first fully automated unattended PCR testing system capable of 24/7 operation, along with STAgora™, a real-time big data analytics platform for clinical decision support. The CURECA system automates the entire PCR workflow including sample preparation for diverse specimen types—addressing a long-standing laboratory bottleneck—while reducing manual labor requirements and improving result consistency. Seegene is offering early pilot partnership programs for these technologies and has established US subsidiaries including Seegene Technologies and Seegene CURECA to strengthen its manufacturing and R&D capabilities in the United States.PR NewswireSeegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025Seegene Inc. unveiled CURECA™, the world's first fully automated PCR testing system that handles the entire testing process from sample storage to result analysis without human intervention, along with STAgora™, a global diagnostic data analytics platform, at the ADLM 2025 conference in Chicago from July 28-31. The CURECA™ system addresses longstanding laboratory automation challenges, particularly in pre-treatment of diverse sample types including stool, reducing labor demands and enabling 24/7 continuous operation. Seegene is offering early pilot partnerships to selected institutions and has established US subsidiaries including Seegene Technologies and Seegene CURECA to strengthen its R&D and manufacturing capacity in the United States, though the products remain in pre-commercialization phase.BioSpaceSeegene Technologies, Inc. Announces Name Change to Seegene USA, Inc.Company expands presence and support in US marketSeegene Technologies, Inc. announced it will change its name to Seegene USA, Inc., effective January 1, 2023, to reflect an expanded presence in the U.S. market. The company will operate from a new location in Irvine, California, while continuing to offer its diagnostic products and services under the new entity.GlobeNewswireSeegene Technologies, Inc. Announces Name Change to Seegene USA, Inc.Seegene Technologies, Inc. has officially changed its name to Seegene USA, Inc., effective January 1, 2023, to reflect its expanding operational presence in the United States. The company will operate from a new location in Irvine, California, while continuing to offer its molecular diagnostics products and services under the new entity.NewswireSeegene Technologies, Inc. Announces Name Change to Seegene USA, Inc.Seegene Technologies, Inc. will change its name to Seegene USA, Inc. effective Jan. 1, 2023, reflecting an expanded U.S. presence. The company will operate from a new Irvine, CA location, offering its Novaplex assay reagents and Allplex SARS-CoV-2 assay with FDA EUA.PR NewswireSeegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiarySeegene Inc., South Korea's leading molecular diagnostics company, appointed Dr. Glen Hansen as Head of Scientific and Medical Affairs of its U.S. subsidiary, Seegene Technologies. This is the second leadership appointment for the U.S. subsidiary in less than a month, following the late February appointment of Richard Creager as CEO, as Seegene aims to expand its U.S. operations from sales to R&D, local production, and financial affairs. The company expects these appointments to help increase its share in the U.S. molecular diagnostics market and drive adoption of its products across COVID and non-COVID assay portfolios.PR NewswireSeegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. businessSeegene Inc., a South Korean molecular diagnostics company, has appointed Richard S. Creager, Ph.D. as CEO of its U.S. subsidiary, Seegene Technologies. Dr. Creager, formerly chief science officer at Beckman Coulter, brings decades of in vitro diagnostics and molecular diagnostics experience to expand the company's presence in the U.S., the world's largest molecular diagnostics market. The appointment supports Seegene's strategy to replicate its global MDx success domestically through product development, M&A, and strategic alliances.PR NewswireSeegene Highlights Clinical Automated Nucleic Acid Extraction System at ASM Microbe 2019Seegene Inc., a South Korean molecular diagnostics company, announced the completion of FDA registration for its automated nucleic acid extraction instrument, the Seegene STARlet, and will begin offering the instrument along with Universal Extraction Cartridge Kits in the U.S. market. The system, developed in partnership with Hamilton Company, can process 94 samples in approximately two hours and accommodates various sample types including swabs, blood, and stool. Seegene Technologies, the company's U.S. subsidiary based in Walnut Creek, California, will lead domestic sales and marketing efforts, with additional FDA registrations for PCR setup and other functions planned by end of 2019.